Introduction {#s1}
============

Recently, for secondary prevention of many kinds of coronary heart disease (CHD) and thrombotic diseases [@pone.0097328-Hermosillo1], [@pone.0097328-Dewilde1], antithrombotic agents (ATA), including anti-platelet agents (APA) such as aspirin and anticoagulants such as warfarin, have been widely prescribed for patients, and sometimes two or more types of ATA are used concomitantly [@pone.0097328-Hermosillo1], [@pone.0097328-Dewilde1], [@pone.0097328-Steinhubl1], [@pone.0097328-Hennekens1]. Among patients receiving ATA, bleeding complications such as intracerebral hemorrhage (ICH) are becoming the issue of most concern.

The Japanese population shows a relatively high incidence of ICH according to the Hisayama [@pone.0097328-Kiyohara1] and Shibata [@pone.0097328-Tanaka1] studies. According to reports from the Japanese Ministry of Health, Labour, and Welfare, cerebrovascular disease (including ICH, cerebral infarction, and subarachnoid hemorrhage) is the third most common cause of death in Japan. Furthermore, in Japan as well as other countries, ICH is among the major causes of stroke. For example, ICH is the second-most common cause of stroke in Italy [@pone.0097328-Sacco1], and is responsible for 15% of strokes reported in the USA [@pone.0097328-Rincon1].

With this background, increasing concern has emerged about the possibility of an ICH in patients receiving APA for a background chronic medical condition. The actual risk of ICH with APA is estimated as 0.2--0.3% per year [@pone.0097328-Hankey1]. Several articles have recently been published showing inferior prognosis of ICH patients who are taking APA compared to those without APA treatment [@pone.0097328-Creutzfeldt1], [@pone.0097328-Roquer1], [@pone.0097328-Toyoda1], [@pone.0097328-Thompson1]. The predominant APAs are cyclooxygenase-1 inhibitors such as aspirin [@pone.0097328-Hennekens2], [@pone.0097328-Fitzgerald1] and anti-P2Y12 antagonists [@pone.0097328-Wijeyeratne1], [@pone.0097328-Sarafoff1], [@pone.0097328-FloresRunk1] such as clopidogrel and ticlopidine. The efficacy of APA varies depending on the genetic background of the patient [@pone.0097328-Fitzgerald1], [@pone.0097328-Jinnai1], [@pone.0097328-Eikelboom1]. However, to date, laboratory examinations have not been routinely and widely applied to check the effects of APA. To recover the platelet functions inhibited by APA, supplying platelets with normal function in the form of platelet transfusion (PLT) might seem efficacious. Although several reports have described the effects of a PLT on survival of ICH patients who are taking APA, nevertheless the effect of a PLT on the outcome of ICH still remains unclear [@pone.0097328-Creutzfeldt1], [@pone.0097328-Washington1], [@pone.0097328-Naidech1], [@pone.0097328-Ducruet1], [@pone.0097328-Naidech2], [@pone.0097328-Batchelor1]. For example, Creutzfeldt et al reported there was no clear benefit in terms of survival in the administration of a PLT to ICH patients taking APA [@pone.0097328-Creutzfeldt1] and Ducruet et al reported that a PLT did not reduce the frequency of hematoma expansion in ICH patients receiving APA [@pone.0097328-Ducruet1]. In contrast, Naidech et al showed that, in ICH patients, the early use of a PLT improved platelet activity assay results and was associated ultimately with a smaller hemorrhage size and greater independence at 3 months [@pone.0097328-Naidech1]. However, these results were only analyzed using a 2-sample test for equality of proportions, without multivariate regressions methods.

We conducted this present study to clarify the impact of a PLT on survival of patients with ICH after taking APA.

Patients and Methods {#s2}
====================

Ethics {#s2a}
------

The Ethics Committee of Kitasato University School of Medicine approved this study (B12--19). Poster presentation for this research was recommended and Informed consent was not obtained from each patient because of the retrospective nature of the study. Patient information was anonymized and de-identified prior to analysis.

Patients {#s2b}
--------

This retrospective cohort analysis included patients who were newly diagnosed with ICH between January 2006 and June 2011 at the tertiary emergency center of Kitasato University Hospital.

Six types of APAs (aspirin, clopidogrel, ticlopidine, cilostazol, sarpogrelate, and dipyridamole) were being taken by 75 patients. However, only the 66 patients receiving aspirin, clopidogrel, and ticlopidine as an "APA" were basically used in our analyses; patients treated with cilostazol (n = 5) [@pone.0097328-Shinohara1], sarpogrelate (n = 1) [@pone.0097328-Shinohara2], dipyridamole (n = 3) [@pone.0097328-DeSchryver1] were excluded, because these three drugs are widely recognized as lower bleeding risk. However, we used all six APAs as a variable in the "broad APA".

Male and female patients, aged at least 20 years, with a recent ICH diagnosed by computed tomography (CT) scan and no evidence of a traumatic cerebral hemorrhage, were eligible for inclusion in the study. Patients were excluded if they had an ICH with ruptured aneurysm in the brain; bleeding arteriovenous malformations in the brain; a brain tumor; or if the ICH had occurred during pregnancy or just after delivery.

A dedicated multidisciplinary team including attending medical doctors, residents, pharmacists, physiotherapists and nurses, cared for all patients.

Methods followed at the time of diagnosis {#s2c}
-----------------------------------------

The following clinical data were collected on arrival, and reviewed and analyzed: age; sex; Glasgow Coma Scale (GCS) score on arrival, which is scored between 3 and 15, 3 being the worst, and 15 the best; clinical background; complications before onset of ICH; elapsed time, defined as the duration between estimated onset and arrival at our hospital; administration of ATA including APAs and anticoagulants; and laboratory data on arrival, including prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count, and fibrinogen. Administration of a PLT after arrival, and outcomes until the seventh day, and 90^th^ day were then recorded. Neurological outcome at 90^th^ day was also collected. Glasgow outcome scale [@pone.0097328-Jennett1] and modified Rankin scale [@pone.0097328-vanSwieten1] are standard to express the neurological outcome, however, we simplified the neurological outcome scale such as dead, dependently alive, independently alive, because this neurological information was reported from not only healthcare-providers but also non-healthcare-providers such as the patients\' families. Elapsed time was defined as the duration from the onset of the ICH to the date of arrival at our center. Observation time was defined as the duration from the date of onset of the ICH to the date of death or to the end of the follow-up.

CT scans were taken on arrival at the center and 24 hours post-arrival and were used to document the initial ICH location (e.g., subcortical, supratentorial or infratentorial hemorrhage), presence or absence of an intraventricular hemorrhage (IVH), and the volume of hemorrhage (volume of hemorrhage was calculated using a previously published method [@pone.0097328-Kothari1]). On the 24-hour follow-up CT scan, cases showing obvious hemorrhage enlargement (≥10% increase in volume compared with on arrival), IVH, or new hemorrhage were judged as showing disease progression.

Primary endpoints were: 1) mortality at 7th and 90th days, and neurological outcome on the 90th day after arrival; and 2) impact of PLT on survival of patients with ICH.

Statistics {#s2d}
----------

Continuous variables are presented as the median value (25th and 75th percentiles). Relationships between APA and clinical background factors were assessed using the Wilcoxon\'s test. Numerical variables are provided as N (%). Relationships between APA and clinicopathological parameters were assessed using Pearson\'s chi-square test or Fisher\'s exact test, as appropriate.

Multivariate logistic regression analyses and the Cox proportional hazards regression model were used to estimate the independent prognostic effect of APA on outcome within 7 days and within 90 days of arrival by adjusting for age, GCS, liver cirrhosis (LC), hypertension (HT), diabetes mellitus (DM), warfarin, location and volume of ICH, disease progression, laboratory data and transfusions, respectively.

All reported P-values are two-sided. A P-value of 0.05 or less was considered statistically significant. Analyses were performed using SPSS version 17.0 software (SPSS, Chicago, IL).

Results {#s3}
=======

Patient background characteristics, assessment of APA use, and its correlation with clinical parameters {#s3a}
-------------------------------------------------------------------------------------------------------

We enrolled 432 patients with ICH (259 men, 60%) into our study; they had a median age on arrival of 67.0 years (range, 40--95 years). The location of the ICH was subcortical in 72 patients (16.7%), supratentorial in 233 (53.9%), and infratentorial in 133 (30.8%) ([Tables 1](#pone-0097328-t001){ref-type="table"} and [2](#pone-0097328-t002){ref-type="table"}).

10.1371/journal.pone.0097328.t001

###### Patient demographics and background characteristics.

![](pone.0097328.t001){#pone-0097328-t001-1}

                                 All patients with ICH.                           
  ----------------------------- ------------------------ ----------- ------------ ----------
  Factors                              **Total**           **APA**                
                                                            **+**       **−**     
                                       432 (100)          66 (15.3)   366 (84.7)   P-value
  **Male**                              259 (60)          47 (71.2)   212 (57.9)     0.04
  **Complication**                                                                
  *Chronic Renal Failure*               43 (10)           11 (16.7)    32(8.7)      0.047
  *Diabetes mellitus*                  55 (12.7)          16 (24.2)   39 (10.7)     0.002
  *Hypertension*                       388 (89.8)         62 (93.9)   326 (89.1)     0.22
  *Liver cirrhosis*                     21 (4.9)           1 (1.5)     20 (5.5)      0.17
  *Coronary heart disease*              24 (5.6)          15 (22.7)    9 (2.5)     \<0.0001
  *Transient ischemic attack*           26 (6.0)          14 (21.2)    12 (3.3)    \<0.0001
  *Atrial fibrillation*                 15 (3.5)           6 (9.1)     9 (2.5)      0.007
  *Deep vein thrombosis*                4 (0.9)               0        4 (1.1)       0.39
  *Valvular disease of heart*           5 (1.2)            1 (1.5)     4 (1.1)       0.77
  *Warfarin*                            28 (6.5)          10 (15.2)    18 (4.9)     0.002
  **Location**                                                                    
  *Subcortical*                         72(16.7)          13 (19.7)   59 (16.1)      0.47
  *Supratentorial*                     233 (53.9)         34 (51.5)   199 (54.4)     0.67
  *Infratentorial*                     133 (30.8)         19 (28.8)   114 (31.2)     0.7
  **IVH**                              113 (26.2)         17 (25.7)   96 (26.2)      0.94
  **Operation**                        89 (20.6)           5 (7.6)    84 (22.9)     0.004
  **Transfusion**                                                                 
  *Platelet*                            16 (3.7)           6 (9.1)     10 (2.7)      0.01
  *Fresh frozen plasma*                 29 (6.7)           5 (7.6)     24 (6.6)      0.76
  **Disease progression**              247 (57.4)         32(49.2)    215 (58.9)     0.15
  **Outcome at 7th day**                                                          
  *Died*                               166 (38.4)         30 (45.5)   136 (37.2)     0.2
  **Outcome at 90th day**                                                            0.14
  *Died*                               178 (41.2)          31 (47)    147 (40.2)  
  *Alive (independent)*                65 (15.0)           6 (9.1)    59 (16.1)   
  *Alive (dependent)*                  63 (14.6)           6 (9.1)    57 (15.6)   
  *Lost of follow up*                  126 (29.2)         23 (34.8)   103 (28.1)  

Numerical variates are given as N (%) and are compared with the

chi-square test or Fisher\'s exact test, as appropriate.

N.D.:not done.

ICH: intracerebral hemorrhage. APA: anti-platelet agents.

IVH: intraventricular hemorrhage.

10.1371/journal.pone.0097328.t002

###### Patient characteristics.

![](pone.0097328.t002){#pone-0097328-t002-2}

                                      Patients with ICH                                          
  ---------------------------- ----- ------------------- ------------------- ------------------- ----------
  **Age**                       432      67 (57, 75)         74 (64, 78)         65 (56,74)       \<0.0001
  **Observation time(day)**     432   33.5 (2.0, 151.3)     11 (2, 104.5)       38.5 (2, 174)       0.13
  **Elapsed time(hour)**        431       2 (1, 3)          1.5 (1, 2.3)           2 (1,3)          0.53
  **Glasgow Coma Scale**        432       6 (4,13)            7 (4,13)           6.5 (4,13)         0.92
  **Volume of hemorrhage**      427     68 (27, 168)      83 (34.8, 185.5)    65.3 (26.8, 168)      0.39
  **Laboratory data**                                                                            
  ***Platelet (10^4^/µL)***     427   19.6(15.6, 24.7)    18.7 (16.0, 22.1)   19.7 (15.5, 24.9)     0.42
  ***Prothrombin time (%)***    423     97 (86, 103)      95 (80.5, 100.3)      98 (88, 105)        0.01
  ***aPTT (sec)***              422   31.1 (27.9, 34.6)   33.2 (29.3, 36.8)   30.8 (27.7, 34.4)    0.008
  ***Fibrinogen (mg/dL)***      419    347 (291, 413)     371 (313.5, 463)    339.5 (289,402.5)     0.01

Continous variables are presented as median (25, 75 percentile) and are compared using the Wilcoxon\'s test.

Elasped time: time at arrival at emergency treatment center minus estimated onset time.

aPTT: activated partial thromboplastin time. APA: anti-platelet agents.

Of these patients, 66 (15.7%) had been prescribed APA prior to ICH onset, comprising aspirin (n = 50, 75%), aspirin and clopidogrel (n = 12, 18.2%), or clopidogrel or ticlopidine (each n = 2, 3.0%) ([Table 3](#pone-0097328-t003){ref-type="table"}).

10.1371/journal.pone.0097328.t003

###### Details of anti-platelet agents.

![](pone.0097328.t003){#pone-0097328-t003-3}

  Agents                   Number (%) patients
  ----------------------- ---------------------
  Aspirin only                  50 (75.0)
  Aspirin + clopidogrel         12(18.2)
  Clopidogrel only               2 (3.0)
  Ticlopidine                    2 (3.0)

Numerical variables are given as N (%).

Regarding the reasons for APA administration, there was a statistically significantly greater incidence of DM (P = 0.047), coronary heart disease (CHD) (P\<0.0001), and transient ischemic attack (TIA) (P\<0.0001) among patients taking APAs compared with patients who were not ([Table 1](#pone-0097328-t001){ref-type="table"}). PLT and fresh frozen plasma (FFP) transfusion were administered to 16 (3.7%) and 29 (6.7%) patients, respectively. The decision to administer a PLT to patients also taking an APA was made by the attending doctors, who may have been concerned about bleeding tendencies due to APA. On the other hand, PLT was also given to patients without APA because of lower platelet counts (\<1×10^5^/µL) (n = 6, range of platelet value; 4.0∼9.6×10^4^/µL, mean platelet value; 7.6×10^4^/µL) according to CNS guideline[@pone.0097328-Samama1], coagulopathy because of warfarin and CRF (n = 2) and unknown reason (n = 2). By day 7 and by day 30, respectively, 166 (38.4%) and 178 (41.2%) patients had died due to an ICH ([Table 1](#pone-0097328-t001){ref-type="table"}).

Characteristics of patients taking APAs, assessment of platelet transfusions received, and their correlation with clinical parameters ([Tables 4](#pone-0097328-t004){ref-type="table"} and [5](#pone-0097328-t005){ref-type="table"}) {#s3b}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

10.1371/journal.pone.0097328.t005

###### Patient Characteristics.

![](pone.0097328.t005){#pone-0097328-t005-5}

                                     Patients with ICH and APA                      
  ---------------------------- ---- --------------------------- ------------------- -------
  **Age**                       66        73.5 (66, 76.3)           74 (64, 78)      0.74
  **Observation time(day)**     66       193 (82.8, 1257)          7.5 (2, 78.5)     0.006
  **Elapsed time(hour)**        66         1.5 (1, 2.75)           1.5 (1, 2.75)     0.84
  **Glasgow Coma Scale**        66          12 (6.8,12)              6 (4,12)        0.07
  **Volume of hemorrhage**      65        87.5 (50,150.8)         83 (32.2, 198)     0.91
  **Laboratory data**                                                               
  ***Platelet (10^4^/µL)***     65       19.3 (14.9,27.3)         18.7 (16, 21.9)    0.85
  ***Prothrombin time (%)***    66         80 (50, 91.5)         95 (82.3, 100.8)    0.14
  ***aPTT (sec)***              66       35.4 (27.1, 36.6)       33.1 (29.5, 37.2)   0.86
  ***Fibrinogen (mg/dL)***      65     330.5 (253.5, 432.5)       371 (314, 463)     0.25

Continous variables are presented as median (25, 75 percentile) and are compared using the Wilcoxon\'s test.

Elasped time: time at arrival at emergency treatment center minus estimated onset time.

aPTT: activated partial thromboplastin time. APA: anti-platelet agents.

66 patients with an ICH (47 men, 71.2%), with a median age on arrival of 74.0 years, had previously received an APA and were grouped according to whether or not they subsequently received a PLT. No statistically significant differences were observed between two groups with respect to their baseline characteristics. There were no deaths among the 6 patients who had taken an APA and received a PLT compared with 30 deaths among the 60 patients in the 'APA with no PLT' group (P = 0.03; [Table 4](#pone-0097328-t004){ref-type="table"}). Thus, PLT seemed to be an effective treatment for patients with ICH who were taking an APA. And APA with PLT patients seemed to show better neurological outcome at 90^th^ day, although it was difficult to assess the neurological outcome because 34.8% patients were lost to follow up.

10.1371/journal.pone.0097328.t004

###### Patient demographics and background characteristics.

![](pone.0097328.t004){#pone-0097328-t004-4}

                                 Patients with APA.                                         
  ----------------------------- -------------------- -------------------------- ----------- ---------
  Factors                            **Total**        **platelet transfusion**              
                                                               **+**               **−**    
                                      66 (100)                6 (9.1)            60 (90.9)   P-value
  **Male**                           47 (71.2)                 5 (83)             42 (70)     0.49
  **Complication**                                                                          
  *Chronic Renal Failure*            11 (16.7)                   0               11(18.3)     0.25
  *Diabetes mellitus*                16 (24.2)                1 (16.7)           15 (25.0)    0.65
  *Hypertension*                     62 (93.9)                5 (83.3)           57 (95.0)    0.32
  *Liver cirrhosis*                   1 (1.5)                    0                1(1.7)      0.75
  *Coronary heart disease*           15 (22.7)                 3 (50)             12 (20)     0.09
  *Transient ischemic attack*        14 (21.2)                1(16.7)            13 (21.7)    1.00
  *Atrial fibrillation*               6 (9.1)                 1(16.7)             5 (8.3)     0.45
  *Deep vein thrombosis*                 0                       0                   0        N.D.
  *Valvular disease of heart*         1 (1.5)                    0                1 (1.7)     1.00
  *Warfarin*                         10 (15.2)                2 (33.3)           8 (13.3)     0.33
  **Location**                                                                              
  *Subcortical*                      13 (19.7)                 1 (25)            12 (20.0)    1.00
  *Supratentorial*                    34(51.5)                2 (33.3)           32 (53.3)    0.42
  *Infratentorial*                   19 (28.8)                 3 (50)            16 (26.7)    0.34
  **IVH**                            17 (25.8)                2 (33.3)           15 (25.0)    0.64
  **Operation**                       5 (7.6)                  3 (50)             2 (3.3)    0.0001
  **Transfusion**                                                                           
  *Platelet*                          6 (9.1)                 6 (100)            60 (90.9)    0.64
  *Fresh frozen plasma*               5 (7.6)                 2 (33.3)            3 (5.0)     0.06
  **Disease progression**            32 (49.2)                 3 (50)            29 (49.2)    1.00
  **Outcome at 7th day**                                                                    
  *Died*                             30 (45.5)                   0                30 (50)     0.03
  **Outcome at 90th day**                                                                     0.008
  *Died*                              31 (47)                    0               31 (77.5)  
  *Alive (independent)*                6 (14)                 2 (66.7)            4 (10)    
  *Alive (dependent)*                  6 (14)                 1 (33.3)           5 (12.5)   
  *Lost of follow up*                23 (34.8)                 3 (50)            20 (33.3)  

Numerical variates are given as N (%) and are compared with the

chi-square test or Fisher\'s exact test, as appropriate.

N.D.:not done.

ICH: intracerebral hemorrhage. APA: anti-platelet agents.

IVH: intraventricular hemorrhage.

Association between APA and mortality at the 7th day after arrival ([Table 6](#pone-0097328-t006){ref-type="table"}) and at the 90^th^ day ([Table 7](#pone-0097328-t007){ref-type="table"}) {#s3c}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Before multivariate analysis, a correlation coefficient matrix of variables was made, and the Kendall tau correlation coefficients between variables were less than 0.6, indicating no strong multicollinearity among our selected variables.

Variables were included in the multivariate logistic regression analysis using the forced entry method. Multivariate logistic regression analysis indicated APA (odds ratio (OR), 5.12; 95% confidence interval (CI), 1.59--16.5; P = 0.006), lower GCS (OR, 0.64; 95% CI, 0.57--0.74; P\<0.0001), and disease progression (OR, 32; 95% CI, 10.24--99.7; P\<0.0001) as independent risk factors for death by day 7 ([Table 6](#pone-0097328-t006){ref-type="table"}, Model 1). Furthermore, when we used the category "broad APA" as a variable in the analysis instead of APA, the OR decreased to 2.7 from 5.12 of APA ([Table 6](#pone-0097328-t006){ref-type="table"}, Model 5).

10.1371/journal.pone.0097328.t006

###### Impact of platelet transfusion and patient factors on the mortality at day 7.

![](pone.0097328.t006){#pone-0097328-t006-6}

                                                                   Model 1   Model 2   Model 3     Model 4     Model 5                                                                                                                                                 
  ----------------------- -------- ------ ---------- ------------ --------- --------- ---------- ------------ --------- ------- ---------- ------------ -------- ------- ---------- ------------- -------- ------- ---------- ------------- ------- ------- ---------- -------------
  Age                       0.01    1.01     0.19     0.99-1.03     0.03      1.03       0.1      1.00-1.06     0.02     1.02      0.22     0.99-1.05     0.02    1.02      0.2       0.98-1.05     0.03    1.03      0.1       1.00-1.06    0.03    1.03      0.04      1.00-1.06
  Sex                       0.03    1.01     0.67     0.72-1.69                                                                                                                                                                                                        
  Elapsed time             -0.01    0.98     0.29     0.96-1.01                                                                                                                                                                                                        
  Glasgow coma scale       -0.55    0.57   \<0.0001   0.50-0.64     -0.44     0.64     \<0.0001   0.57-0.74     -0.43    0.66    \<0.0001   0.57-0.75    -0.43    0.65    \<0.0001    0.57-0.74    -0.43    0.65    \<0.0001    0.57-0.74    -0.44   0.65    \<0.0001    0.57-0.73
  Chronic Renal Failure     0.47    1.61     0.14     0.85-3.02                                                                                                                                                                                                        
  Liver cirrhosis           1.22    3.3      0.02     1.30-8.56     0.88       2.4       0.24     0.55-10.5     0.92      2.5      0.25     0.52-12.0     0.9     2.47      0.25      0.53-11.4     0.9     2.47      0.24      0.54-11.2    0.82    2.27      0.28      0.52-9.86
  Hypertension             -0.13    0.88     0.72     0.42-1.82     -0.71     0.43       0.28     0.14-1.77     -0.59    0.56      0.39     0.15-2.14    -0.65    0.52      0.34      0.14-1.99    -0.56     0.4      0.57      0.15-2.11    -0.65   0.52      0.31      0.15-1.83
  CHD                       0.35    1.41     0.48     0.54-3.67                                                                                                                                                                                                        
  Diabetes mellitus        -0.58    0.56     0.12     0.27-1.15     -0.56     0.57       0.30     0.20-1.66     -0.6     0.55      0.29     0.18-1.66     -0.6    0.55      0.29      0.18-1.67    -0.63    0.53      0.18      0.12-1.57    -0.48   0.62      0.37      0.22-1.76
  Atrial fibrillation      -1.05    0.34     0.33     0.04-2.95                                                                                                                                                                                                        
  TIA                       0.47    1.60     0.32     0.63-4.05                                                                                                                                                                                                        
  Anti-platelet agents      0.17    1.18     0.61     0.62-2.24     1.63      5.12      0.006     1.59-16.5     1.91     6.78     0.004     1.84-24.9     1.78    5.91     0.006      1.68-20.9     1.86    6.48     0.003      1.88-22.3                              
  Warfarin                  0.35    1.42     0.37     0.66-3.07     -0.28     0.76       0.7       0.18-3.1     0.37     1.44      0.67     0.27-7.68     0.25    1.28      0.77      0.25-6.51     0.03    1.03      0.97      0.23-4.71    -0.19   0.83      0.8        0.2-3.4
  Broad APA                 0.15    1.16     0.57     0.70-1.92                                                                                                                                                                              0.99     2.7      0.06      0.95-7.63
  Location                                                                                                                                                                                                                                                             
  subcortical              -0.24    0.79     0.43     0.44-1.43                                                                                                                                                                                                        
  supratentorial           -0.33    0.72     0.14     0.47-1.11                                                                                                                                                                                                        
  infratentorial            0.73    2.01    0.002     1.31-3.28     0.23      1.26       0.53      0.61-2.6     0.36     1.42      0.36     0.67-3.03     0.37    1.28      0.76      0.68-3.07     0.23    1.25      0.55      0.60-2.61    0.24    1.27      0.52      0.62-2.60
  Volume of ICH            0.003    1.01   \<0.0001   1.006-1.01    0.003     1.003      0.06     1.00-1.01     0.004    1.004     0.04       1-1.01     0.004    1.002     0.04      1.00-1.01    0.003    1.003    0.046       1-1.007     0.003   1.003     0.06       1-1.006
  Disease progression       3.96    52.5   \<0.0001   20.6-133.9    3.46       32      \<0.0001   10.24-99.7     3.5     33.1    \<0.0001   10.1-108.1    3.47    32.2    \<0.0001   10.1-102.6     3.51    33.4    \<0.0001   10.4-107.7    3.28    26.6    \<0.0001    9.18-77.2
  Operation                 0.63    1.89   \<0.0001   1.39-2.54                                                                                                                                                                                                        
  IVH                       0.20    1.23     0.40     0.76-1.97                                                                                                                                                                                                        
  Platelet count           -0.04    0.96    0.011     0.93-0.99    -0.006     0.98       0.47     0.93-1.03     -0.04    0.97      0.21     0.91-1.02    -0.03    0.97      0.22      0.92-1.02    -0.03    0.97      0.32      0.92-1.03    -0.02   0.98      0.32      0.93-1.03
  PT                       -0.02    0.99    0.001     0.98-0.99                                                                                                                                                                                                        
  aPTT                      0.04    1.02     0.11     0.99-1.05                                                                                                                                                                                                        
  Fibrinogen               -0.001   1.00     0.52     0.99-1.00     0.001       1        0.8      0.93-1.03     0.001      1       0.98     1.00-1.01    0.0001     1       0.98     0.997-1.003   0.0001     1       0.91     0.997-1.003   0.001   1.001     0.72     0.998-1.003
  Platelet transfusion     -0.98    4.02     0.07     0.90-18.1                                                 -1.49    0.23      0.26     0.02-3.02                                              -2.62    0.03      0.07      0.01-0.75                              
  FFP transfusion           1.44    4.20    0.009     1.44-12.3                                                 2.23     0.04     0.008     1.81-48.0     2.59    13.3     0.001      2.85-62.6                                                                        

CHD: coronary heart disease; PH of TIA: past history of transient ischemic attack; APA: anti-platelet agents; IVH: intraventricular hemorrhage.

ICH: intracerebral hemorrhage; PT: prothrombin time; aPTT: activated partial thromboplastin time; OR: odds ratio; CI: confidence interval.

By way of precaution, we tried both the forward and backward methods for selecting variables after our analyses, and GCS, APA, and disease progression were all selected by both methods.

By cox proportional hazards regression analysis, APA was the independent risk factor for the survival at the 90^th^ day (hazard ratio, 1.87; 95% CI, 1.20--2.91; P = 0.006) ([Table 7](#pone-0097328-t007){ref-type="table"}).
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###### Impact of platelet transfusion and patient factors on the mortality at day 90.
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                                                                          Model 1                        Model 2                     
  --------------------------- -------- ------- ---------- -------------- --------- ------- ---------- ------------- -------- ------- ----------
  **Age**                       0.01    1.01      0.19      0.99--1.02     0.01     1.01      0.1      0.99--1.02     0.01    1.01      0.22
  **Sex**                       0.07    1.01      0.67      0.79--1.45                                                               
  **Elapsed time**             −0.02    0.98      0.10     0.96--1.004                                                               
  **Glasgow coma scale**       −0.38    0.68    \<0.0001    0.64--0.73     −0.28    0.76    \<0.0001   0.69--0.82    −0.27    0.77    \<0.0001
  **Chronic Renal Failure**     0.28    1.33      0.21      0.85--2.08                                                               
  **Liver cirrhosis**           0.85    2.33     0.002      1.37--3.95     0.51      1.7      0.13     0.86--3.22     0.59     1.8      0.25
  **Hypertension**             −0.09    0.91      0.71      0.57--1.49     −0.26    0.77      0.35     0.45--1.33    −0.21    0.81      0.39
  **CHD**                       0.35    1.41      0.51      0.48--3.67                                                               
  **Diabetes mellitus**        −0.15    0.86      0.52      0.55--1.36     −0.15    0.86      0.58     0.51--1.47    −0.17    0.84      0.29
  **Atrial fibrillation**      −1.05    0.34      0.33      0.04--1.95                                                               
  **TIA**                       0.47    1.60      0.32      0.63--3.04                                                               
  **Anti-platelet agents**      0.21    1.24      0.28      0.84--1.82     0.62     1.87     0.006     1.20--2.91     0.64     1.9     0.004
  **Warfarin**                  0.26    1.30      0.37      0.74--2.28      0.1     0.76      0.76     0.59--2.04     0.21    1.24      0.67
  **Location**                                                                                                                       
  *subcortical*                −0.13    0.88      0.54      0.59--1.32                                                               
  *supratentorial*             −0.26    0.77      0.08      0.57--1.04                                                               
  *infratentorial*              0.48    1.61     0.002      1.19--2.18     0.08     1.08      0.69     0.74--1.56     0.06    1.07      0.36
  **Volume of ICH**            0.004    1.004   \<0.0001   1.003--1.005    0.001    1.001     0.06     1.00--1.003   0.001    1.001     0.06
  **Disease progression**       2.94    18.9    \<0.0001   9.98--35.95     2.43     11.3    \<0.0001   4.84--26.6     2.4     11.5    \<0.0001
  **Operation**                 0.63    1.89    \<0.0001    1.39--2.54                                                               
  **IVH**                       0.20    1.23      0.40      0.76--1.97                                                               
  **Platelet count**           −0.04    0.96     0.001      0.94--0.99     0.001    1.001     0.95     0.98--1.03    −0.001   0.97      0.21
  **PT**                       −0.009   0.99     0.002      0.98--0.99                                                               
  **aPTT**                     0.001    1.02      0.99      0.99--1.01                                                               
  **Fibrinogen**               −0.001   1.00      0.29     0.99--1.001     0.001      1       0.81     0.99--1.002   0.001      1       0.98
  **Platelet transfusion**     −0.97    0.38      0.09      0.12--1.18                                               −1.74    0.18      0.09
  **FFP transfusion**           1.08    2.96      0.02      1.21−7.18                                                                

CHD: coronary heart disease; TIA: transient ischemic attack; APA: anti-platelet agents; IVH: intraventricular hemorrhage.

ICH: intracerebral hemorrhage; PT: prothrombin time; aPTT: activated partial thromboplastin time; HR:hazard ratio; CI: confidence interval.

Impact of PLT on survival within 7 days after arrival of those patients with an ICH, who were also taking an APA {#s3d}
----------------------------------------------------------------------------------------------------------------

Administrations of a PLT and/or FFP were added as a variable to our model ([Table 6](#pone-0097328-t006){ref-type="table"}, Models 2--4). The use of APA was still an independent prognostic factor in these analyses, and PLT seemed to be beneficial to the survival of ICH patients (Model 2, 4), regardless of the use of APA. The OR of APA increased from 5.12 (95% CI, 1.59--16.5; P = 0.006) in the Model 1 to 6.48 (95% CI, 1.88--22.3; P = 0.003) in the Model 4 because of the small number of events, an assumption that was drawn from the widening of the 95% CI.

Discussion {#s4}
==========

We assessed the effects of prior administration of APA on patients with ICH, which yielded several important results. First, we confirmed that APA worsened survival in patients with ICH within 7 days and 90 days after arrival at the emergency center. Second, giving a PLT to ICH patients who were taking an APA was a favorable factor for survival.

First, to discuss our finding that taking an APA worsened survival in patients with an ICH within 7 days after arrival, two possibilities may explain this result: 1) the mode of action of APAs; and 2) the underlying disease that had been controlled by APA therapy.

APAs inhibit the activation and aggregation of platelets after vascular injury, and thus induce a bleeding tendency, so we can easily imagine disease progression after the onset of ICH in patients taking APAs. According to the Bleeding with Anti-Thrombotic therapy (BAT) study, incidences of ICH reported in cases administered a single APA, two types of APA, warfarin only, or APA with warfarin were 0.34%, 0.60%, 0.62%, and 0.96%, respectively [@pone.0097328-Toyoda2]. In our study, 50 of 66 patients had been prescribed a single APA, and 12 had been prescribed two APAs. For patients with warfarin, measuring PT regularly is an efficient and very easy way to prescribe the proper dose of warfarin. Furthermore, treatment strategies for patients with an ICH who are also taking warfarin have been largely established, and include the use of vitamin K, FFP, and prothrombin complex concentrates [@pone.0097328-Butler1], [@pone.0097328-Flaherty1], [@pone.0097328-Flibotte1]. For patients with an ICH who are taking APA, treatment strategies to recover platelet function have not been established, yet.

In terms of the second possibility, patients who need APA have atherosclerotic diseases such as CHD or TIA, which are considered as risk factors for survival of ICH. Among our patients receiving APA, 15 patients (22.7%) had CHD and 14 (21.2%) had experienced a TIA.

Second, to discuss our finding that giving a PLT to ICH patients taking APA was a favorable factor for survival ([Table 4](#pone-0097328-t004){ref-type="table"}). In previous studies, the effects of PLT on spontaneous ICH cases taking APAs were unclear. We suggest that the key to solving this uncertainty is to establish when a PLT should be given and to whom.

To address the first question of timing of administration of the PLT, which is important to stop hematoma expansion (HE). Naidech reported [@pone.0097328-Naidech1] that administration of a PLT within 12 hours led to good neurological results; unfortunately, their results were not analyzed by multivariate regression. Several studies have indicated that early HE occurs in 18--38% of patients scanned within 3 hours of ICH onset, and more than 70% develop at least some degree of HE within 24 hours of symptom onset, even in the absence of known coagulopathy, suggesting an active bleeding process in the hyper acute phase of ICH [@pone.0097328-Balami1]. Unfortunately, we could not check the actual timing of PLT administration, although it appeared to be more than 6 hours after arrival. The median elapsed time from onset was 2 hours ([Table 2](#pone-0097328-t002){ref-type="table"}). After arrival at our hospital, checking neurological symptoms, eliciting the patient\'s medical and drug histories from the family, laboratory examinations, and a CT examination were performed simultaneously. As a result, in our hospital, at least 6 hours may have elapsed before considering and ordering PLT.

Secondly, to address the question of which patients truly need a PLT after developing an ICH while taking APAs. The negative impact of unnecessary administration of PLT includes over-coagulation and effects of the cytokines associated with the PLT will be concerned. After ICH onset, decreased blood flow to the area surrounding the clot causes local neuronal ischemia, leading to further cytotoxic edema and the toxic release of excitatory amino acids and inflammatory mediators [@pone.0097328-Dearden1]. On diffusion-weighted imaging, a significant number of ICH patients show acute ischemic lesions that are not contiguous with the hematoma [@pone.0097328-Menon1], [@pone.0097328-Garg1]. A PLT may induce unnecessary thrombus in and around the ischemic area, resulting in enlargement of the ischemic lesion and worsening of the brain injuries.

The ICH area shows thrombin-induced activation of the inflammatory cascade [@pone.0097328-Lee1] and overexpression of matrix metalloproteinase (MMPs), representing additional mechanisms contributing to breakdown of the blood-brain barrier, brain edema growth and neuronal death, all of which are recognized as secondary brain injuries after the onset of ICH [@pone.0097328-FlorczakRzepka1]. Platelets are the major supplier of MMPs [@pone.0097328-Seizer1], and therefore brain injury may be worsened by a PLT, as it will provide an inflammatory stimulus to the injured brain.

Aspirin resistance is also a well-known phenomenon [@pone.0097328-Fitzgerald1], [@pone.0097328-Eikelboom1], and has been well observed in Japan [@pone.0097328-Miyata1]. Furthermore, 60% of Japanese are low responders to clopidogrel because of a CYP2C19 polymorphism [@pone.0097328-Jinnai1], [@pone.0097328-Hoshino1]. However, easy, fast, and low-cost laboratory examinations to monitor the effect of APA on an individual patient\'s platelets are not readily available. For some patients, a certain dose may not be sufficient to prevent thrombotic events, while for others, that same dose might cause dangerous bleeding complications such as ICH. For low responders to APA, in whom platelet function and coagulation parameters are normal, even when given concomitantly with APA, PLT might induce over-coagulation around the ICH site.

Taking drug resistance into consideration, clarification of the effects of PLT on ICH prognosis will require a prospective cohort study with monitoring of the effects of APA.

A key limitation in this study was the short duration of observation, because patients were often moved to other institutions within a short period of time following admission, due to limited capacity at our hospital. In addition, we need an increased sample size to evaluate better the PLT effect in the multivariate regression analysis. Another disadvantage in this study was that the decision to give a PLT depended on the resident neurosurgeon. However, the strength of our study was that this was the first to look at the effect of PLT in a population of Asian patients with ICH plus concomitant APA; all three previous studies have dealt mainly with Caucasian patients [@pone.0097328-Creutzfeldt1], [@pone.0097328-Naidech1], [@pone.0097328-Ducruet1]. As Asian people tend to be APA resistant, PLT seemed to be less necessary compared with Caucasians even in cases of ICH with APA. Finally, as this was a single-institution study, our patients were evaluated using consistent methods and procedures.

To evaluate the true effects of PLT on ICH survival, animal models and prospective stratified cohorts taking into account the effects of APAs are necessary.
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